Clinical Research Capabilities Bioavailability & Bioequivalence Studies Clinical Research Division

Size: px
Start display at page:

Download "Clinical Research Capabilities Bioavailability & Bioequivalence Studies Clinical Research Division"

Transcription

1

2 Clinical Research Capabilities Bioavailability & Bioequivalence Studies Clinical Research Division

3 03 CLINICAL RESEARCH SERVICES

4 VIMTA STRENGTHS Experience 32 years of track record in supporting Pharma& Life Sciences industries A Truly Independent CRO Not affiliated to any Pharmaor Life Sciences organization Core Value Integrity of service through honesty, responsibility and uncompromising devotion to Quality Strong Regulatory Compliance Long standing experience in working as per different regulatory frameworks One-stop-shop for testing your generic pipeline knowledgeable, experienced, motivated and committed team Effective and Efficient Project Management 04

5 Bioavailability & Bioequivalence Studies 05

6 REGULATORY AUDIT EXPERIENCE REGULATOR NO. OF INSPECTIONS DCGI (India) 4 FDA (USA) 10 MHRA (UK) 2 BfArM (Germany) 2 ASNM (France) 2 WHO 4 DRAs of Denmark, Portugal & Sweden* MCC (South Africa) 2 ANVISA (Brazil) 2 NPCB (Malaysia)

7 BA/BE SERVICES Full service for BA/BE studies (1) In healthy volunteers & (2) In patients Study designing & protocol development Method development & validation Pre-study approvals for project initiation Project execution as per protocol and standard procedures Pre & post project regulatory support Statistical data analysis ectd submission Standalone services (Clinic/Bioanalytical/clinical Lab) 07

8 EXPERIENCE Study designing & protocol preparation Cross over, parallel, steady state, average bioequivalence (full/reference replicate designs) Testing of various dosage forms Tablets, capsules, orally disintegrating strips, gels, oral solutions, dermal patches and injectables Execution of studies with large sample size Over 350 validated bio-analytical methods 08

9 EXPERIENCE > 1700 BA/BE studies for customers across the globe Successfully contributed to more than 120 ANDAs and 505.B(2) applications in regulated markets Submissions to regulatory agencies: Regulatory Agency Studies conducted since No. of pivotal studies conducted so far DCGI (India) 1994 >400 USFDA 2000 >300 EU 2001 >50 WHO 2000 >15 Others (Health Canada, TGA, MCC, etc.) 2000 >50 09

10 IT POWERED PROCESSES Biometric solutions for identification of volunteers and cross participation status Audio-Video recording of consent process MedDRA for Adverse Event Coding Analyst software version for LCMS MS Mass Lynx version 4.1 for Micro Mass SAS version 9.2 Enterprise Guide 4.2 WinNonLin version 6.2 for PK analyses Electronic Document Management System SAP for Material Management 10

11 CLINIC 180 beds clinic capacity Healthy Volunteers Database In house volunteer screening facility In house clinical lab for safety assessments Fully equipped ICU to handle medical emergencies Synchronized clock systems (RF mesh network) Pharmacy for controlled storage of Investigational Products High volume centrifuges (temperature controlled)& freezers In-house catering facility to provide standardized food 11

12 CLINICAL LAB Dedicated automated biochemistry analyzers Back-up equipments to ensure continuity Testing for drugs of abuse Accreditations ISO/IEC by NABL (National Accreditation Board for Testing & Calibration Laboratories, India) College of American Pathologists (CAP) 12

13 BIOANALYTICAL Pool of 24 Mass spectrometers for rapid turnaround Different varients of LC MS MS(API 2000/3200/4000 & Micromass) LC MS MS 8050/8060 (for molecules with low sensitivity) GC MS MS(single & triple quadrapole) ICP MS for elemental analysis ELISA analyses for Iron preparations Dedicated equipment & scientists for each project Dedicated QC team for data verification Power backup for all equipments 13

14 SAMPLE STORAGE FACILITIES Cold storage, across 2 Sites in Hyderabad : Eleven Deep Freezers four (-) 20 0 C seven (-) 70 0 C (-) 20 0 C walk-in-chamber Long term data archival facility Dedicated storage facilities for clinical samples, bioanalytical samples, and clinical lab kits with central monitoring facility 14

15 Thank You For Your Time Vimta - CR Division 15

Bioequivalence & Bioavailability (PK/PD) studies

Bioequivalence & Bioavailability (PK/PD) studies Bioequivalence & Bioavailability (PK/PD) studies www.phaps.com We provide economical solution for BE/BA studies Protect public health by providing laboratory services to the pharmaceutical and healthcare

More information

Corporate Presentation Sept 18

Corporate Presentation Sept 18 Corporate Presentation Sept 18 1 About us 1 Global CRO providing comprehensive & integrated offerings for end to end clinical research Full Service Global CRO 2 4 3 Presence in two continents; offices

More information

NUVISAN GROUP. Our Philosophy

NUVISAN GROUP. Our Philosophy NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered

More information

Management Team. Over 35 years experience in the pharmaceuticals industry

Management Team. Over 35 years experience in the pharmaceuticals industry 2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since

More information

Your bridge to. better medicines

Your bridge to. better medicines Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)

More information

About Us Cliantha Research Hill Top Research Inflamax Research Karmic Lifesciences

About Us Cliantha Research Hill Top Research Inflamax Research Karmic Lifesciences Full Service CRO About Us Cliantha is an independent global Contract Research Organization (CRO) providing integrated clinical offerings in Early Phase (Phase I/IIa), Late Phase (Phase II-IV), Bioequivalence

More information

ACHIEVEMENTS OF CDSCO DURING YEAR

ACHIEVEMENTS OF CDSCO DURING YEAR ACHIEVEMENTS OF CDSCO DURING YEAR 2015-2017 E-Governance E-Governance in CDSCO through SUGAM Portal has been launched. Following activities of CDSCO are presently performed through the Sugam Portal: Import

More information

PHARMADAX IMPROVING QUALITY OF LIFE. Pharmadax Inc - Company Presentation 1

PHARMADAX IMPROVING QUALITY OF LIFE. Pharmadax Inc - Company Presentation 1 PHARMADAX IMPROVING QUALITY OF LIFE Pharmadax Inc - Company Presentation 1 Content Overview Mission and Vison Infrastructure Management Team Journey so far. Technology Platforms Products and Services Pharmadax

More information

About Us Cliantha Research Hill Top Research Inflamax Research Karmic Lifesciences

About Us Cliantha Research Hill Top Research Inflamax Research Karmic Lifesciences Full Service CRO About Us Cliantha is an independent global Contract Research Organization (CRO) providing integrated clinical offerings in Early Phase (Phase I/IIa), Late Phase (Phase II-IV), Bioequivalence

More information

Pre-Screening revised checklist for BA/BE NOC for Export Purpose

Pre-Screening revised checklist for BA/BE NOC for Export Purpose Pre-Screening revised checklist for BA/BE NOC for Export Purpose O/o Drugs Controller General (India) Directorate General of Health Services FDA Bhawan, New Delhi (With effective from 25 th April 2014)

More information

Corporate Presentation

Corporate Presentation Corporate Presentation 1 Development Tool Medicine Stabicon Life Sciences Wellness Health Supplement Ethos Vision: Lead the way to a healthier world by partnering with Pharmaceutical Community across the

More information

(MPY-201 DRA) - ADVANCE DRA I

(MPY-201 DRA) - ADVANCE DRA I (MPY-201 DRA) - ADVANCE DRA I (Indian Legislation) The Drugs and Cosmetics act, 1940 and Rules with emphasis on Good laboratory practices and requirements of premises and equipments (Schedule L-I), Good

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION About us. Established in 1973, Micro Labs is a fully integrated pharmaceutical company, present across the entire pharmaceutical value chain from Research and Development, Active

More information

Framework of Regulation /Guidelines

Framework of Regulation /Guidelines Sponsor Responsibility Site Selection Peculiarities of Early Phase Clinical Trials AGAH Workshop, November 03-04, 2016, Bonn Framework of Regulation /Guidelines New Clinical Trial Regulation 536/2014 EU

More information

Portfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO

Portfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated

More information

Anushri Global Pharma Consultants

Anushri Global Pharma Consultants Anushri Global Pharma Consultants Your Knowledge Partner In Training, Consulting & Placement Anushri Global Pharma Consultants A Catalyst to sustainable growth Page 1 of 9 About Us Training is important

More information

Practical Conduct of Clinical Trials

Practical Conduct of Clinical Trials Practical Conduct of Clinical Trials Overview Regulation of clinical trials SA as a clinical trial destination The clinical trial process Phases of clinical development Different study designs Clinical

More information

About Us Cliantha Research Hill Top Research Karmic Lifesciences

About Us Cliantha Research Hill Top Research Karmic Lifesciences Full Service CRO About Us Cliantha is an independent global Contract Research Organization (CRO) providing an integrated clinical offerings in Early Phase (Phase I/IIa), Late Phase (Phase II-IV), Bioequivalence

More information

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39) ZAMRA BTIF BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39) The Guidelines on Bioequivalence Studies to be consulted in completing this form.

More information

Changes Impacting Bioequivalence Inspections: What s New?

Changes Impacting Bioequivalence Inspections: What s New? Changes Impacting Bioequivalence Inspections: What s New? Sam H. Haidar, Ph.D., R.Ph. Division of Generic Drug Bioequivalence Evaluation Office of Study Integrity and Surveillance Center for Drug Evaluation

More information

BIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials

BIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials BIOSCIENTIA Good outcomes are based on good values Central lab services and biomarker analytics for clinical trials BIOSCIENTIA Do you remember when...... US President Ronald Reagan appealed to Michail

More information

Job Openings at SoliPharma

Job Openings at SoliPharma Openings at SoliPharma Posted on Feb 22, 2018 Corporate Overview SoliPharma is a specialty pharmaceutical company established in 2010, with major operation in Hangzhou China and Boston USA. We have full-range

More information

UNIVERSITY OF MUMBAI

UNIVERSITY OF MUMBAI Page 1 of 20 AC 24-06-2016 Item No. 4.66 UNIVERSITY OF MUMBAI Syllabus for Sem I and Sem II, M.Voc Program: M.Voc Course : PHARMA ANALYTICAL SCIENCES (To be Introduced Choice Based Credit System with effect

More information

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets

Int. J. Pharm. Sci. Rev. Res., 31(2), March April 2015; Article No. 04, Pages: A Review on Drug Approval in Regulated and Non-Regulated Markets Review Article A Review on Drug Approval in Regulated and Non-Regulated Markets Vemuri Pavan Kumar, N Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy,

More information

in full-service contract pharmaceutical development and manufacturing

in full-service contract pharmaceutical development and manufacturing in full-service contract pharmaceutical development and manufacturing THE Norwich Advantage Norwich is a recognized leader in full service contract pharmaceutical development and manufacturing. As a single-source

More information

BIOEQUIVALENCE TRIAL INFORMATION

BIOEQUIVALENCE TRIAL INFORMATION PRESENTATION OF BIOEQUIVALENCE TRIAL INFORMATION BIOEQUIVALENCE TRIAL INFORMATION GENERAL INSTRUCTIONS: Please review all the instructions thoroughly and carefully prior to completing the Bioequivalence

More information

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to

The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization

More information

Medicines Control Authority Of Zimbabwe

Medicines Control Authority Of Zimbabwe Medicines Control Authority Of Zimbabwe BIOEQUIVALENCE APPLICATION FORM Form: EVF03 This application form is designed to facilitate information exchange between the Applicant and the MCAZ for bioequivalence

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Handling and Retention of BA and BE Testing Samples U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 2004

More information

Eurofins ADME BIOANALYSES Your partner in drug development

Eurofins ADME BIOANALYSES Your partner in drug development Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant

More information

Formulation Development & CTM Manufacturing Services

Formulation Development & CTM Manufacturing Services Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range

More information

3M Drug Delivery Systems. April 26, 2011

3M Drug Delivery Systems. April 26, 2011 3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation

More information

CMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10

CMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10 CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

TAKE Solutions Limited

TAKE Solutions Limited TAKE Solutions Limited Delivering Domain-intensive Services In Life Sciences March, 2018 At A Glance USA HQ: Princeton, NJ Clinical, Regulatory & Safety consulting and technology centers. Trial operations

More information

Intertek Melbourn Company Presentation. MIBio 2016

Intertek Melbourn Company Presentation. MIBio 2016 Intertek Melbourn Company Presentation MIBio 2016 November 2016 Global Leader in quality solutions across all industries Innovative and bespoke quality solutions for our clients 24/7 FTSE 100 company in

More information

Bioavailability and Bioequivalence Studies

Bioavailability and Bioequivalence Studies Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98

More information

Medicines inspections technical updates: Contract research organizations (CROs)

Medicines inspections technical updates: Contract research organizations (CROs) JOINT UNICEF, UNFPA & WHO MEETING WITH MANUFACTURERS AND SUPPLIERS OF CONTRACEPTIVE DEVICES, IN VITRO DIAGNOSTICS PRODUCTS, VACCINES, FINISHED PHARMACEUTICAL PRODUCTS, ACTIVE PHARMACEUTICAL INGREDIENTS

More information

WELCOME TO SAI PHARMA CONSULTANCY T RAMA RAO HYDERABAD

WELCOME TO SAI PHARMA CONSULTANCY T RAMA RAO HYDERABAD WELCOME TO SAI PHARMA CONSULTANCY T RAMA RAO HYDERABAD About Sai Pharma Consultants Promoter and Principal Consultant Mr. T Rama Rao is having experience of over a period of three decades in Pharma industry

More information

UNIVERSITY OF MUMBAI

UNIVERSITY OF MUMBAI Academic Council 25/05/2011 Item No. 4.71 UNIVERSITY OF MUMBAI Syllabus for Clinical Studies Program: Diploma Course: Post Graduate Diploma in Clinical Studies, Data Management & Medical Writing (Introduced

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

Overview. Mission Background Regulatory Principles Evaluation Routes Data Requirements Regulatory Process Application Statistics

Overview. Mission Background Regulatory Principles Evaluation Routes Data Requirements Regulatory Process Application Statistics 2 December 2010 Innovative Regulatory Review Practices for Better Efficiencies- The Singapore Experience Dr Daniel Tan Director Health Products Regulation Group Health Sciences Authority Copyright HSA

More information

ENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ]

ENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ] ENSURING QUALITY THROUGH COMPLIANCE [ COMPLIANCE ] BEING IN COMPLIANCE HAS NEVER BEEN MORE IMPORTANT Quality encompasses more than meeting regulatory requirements. It extends throughout your organization

More information

A8: Documentation. Team members: Interdependencies with other teams if any. Out of scope. Team lead. Other members

A8: Documentation. Team members: Interdependencies with other teams if any. Out of scope. Team lead. Other members A8: Documentation Team members: Team lead Tom Verhaeghe Janssen R&D EU Other members Eric Woolf Merck NA Hollie Barton PPD NA Marian Kelley Mkelley Consulting NA Myriam Salvadori ChromAnalysis LA Richard

More information

BIOMETRICS SERVICES ADVISORY DATA OFFICE UNBLINDING SECURE INDEPENDENT TEAM PROGRAM. ADaM TRAINER SAFETY SDTM COMPLIANT TA-EXPERTISE SDTM DATA

BIOMETRICS SERVICES ADVISORY DATA OFFICE UNBLINDING SECURE INDEPENDENT TEAM PROGRAM. ADaM TRAINER SAFETY SDTM COMPLIANT TA-EXPERTISE SDTM DATA BIOMETRICS SERVICES DELIVER UNBLINDED DATASETS TO IDMC SDTM-IG UNBLINDING ADVISORY QUALITY ON TIME DEDICATED DATA SECURE BOARD EMERGENCY PARTNERSHIPTEAM DATA OFFICE UNBLINDING INVESTINGEXPERTISE SHARING

More information

Speed Innovation Happiness. Services Overview

Speed Innovation Happiness. Services Overview Services Overview Bilcare GCS Objective To Provide Reliable and Credible Long-term Clinical Trial Material Supplies Partnering with Global Sponsor/CRO to successfully conduct the Clinical Trials, Worldwide

More information

Algorithme Pharma Vince & Associates Clinical Research Algorithme Pharma USA

Algorithme Pharma Vince & Associates Clinical Research Algorithme Pharma USA Algorithme Pharma Vince & Associates Clinical Research Algorithme Pharma USA Over 25 Years of Clinical Research Excellence With facilities in both the US and Canada, Altasciences Clinical Research offers

More information

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION DIRECTORATE GENERAL OF HEALTH SERVICES MINISTRY OF HEALTH AND FAMILY WELFARE GOVERMENT OF INDIA

CENTRAL DRUGS STANDARD CONTROL ORGANIZATION DIRECTORATE GENERAL OF HEALTH SERVICES MINISTRY OF HEALTH AND FAMILY WELFARE GOVERMENT OF INDIA 1 GUIDANCE DOCUMENT FOR BA/BE NOC FOR EXPORT CENTRAL DRUGS STANDARD CONTROL ORGANIZATION DIRECTORATE GENERAL OF HEALTH SERVICES MINISTRY OF HEALTH AND FAMILY WELFARE GOVERMENT OF INDIA GUIDANCE DOCUMENT

More information

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) 5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs) GCP Requirements and Compliance Dr. Katalina Mettke BfArM, Germany Agenda Specialities of Early Development Trials Examples

More information

Official Letter from the DOH

Official Letter from the DOH Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please

More information

Considerations for Successful Biomarker Bioanalysis in Regulated Environment

Considerations for Successful Biomarker Bioanalysis in Regulated Environment Considerations for Successful Biomarker Bioanalysis in Regulated Environment Darshana Jani, M.Sc. Darshana.Jani@pfizer.com 10 th European Bioanalysis Forum November 15, 2017 1 Disclaimer The contents of

More information

GMP. Safeguard The Patient s Health.

GMP. Safeguard The Patient s Health. GMP Safeguard The Patient s Health. Scope. Products and testing according to pharma industry standard. Good Manufacturing Practice or GMP are practices and systems that are required to be adapted in pharmaceutical

More information

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs

Business Units contract development and manufacturing cost effective processes reliability of supply. total API solution retroviral APIs Business Units Building on our strong capabilities in chemical development and manufacturing, Laurus Labs has developed an in-house range of APIs and related intermediates. Focusing on chemistries where

More information

Contact:: (609) Details please visit our website:

Contact:: (609) Details please visit our website: SunGen Pharma aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate

More information

Discover the Importance of Third Party Quality Control

Discover the Importance of Third Party Quality Control Bio-Rad Laboratories Q U A L I T Y C O N T R O L Discover the Importance of Third Party Quality Control Introduce Your Laboratory to an Independent Assessment Bio-Rad Laboratories Q U A L I T Y C O N T

More information

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC)

GMP The Other Side of Chemistry, Manufacturing & Controls (CMC) Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls

More information

ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY

ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY BIOANALYTICAL SOLUTIONS FOR BIOTHERAPEUTICS AND SMALL MOLECULE THERAPEUTICS ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY MARCH 15, 2017 AIT BIOSCIENCE, LLC BIOANALYSIS TO SUPPORT

More information

PLANKSTADT EXPERTS TAKING CARE

PLANKSTADT EXPERTS TAKING CARE CordenPharma PLANKSTADT EXPERTS TAKING CARE Our History 1977 - Start of Packaging activities (ICI Pharma) 1980 - Start of Formulation activities (ICI Pharma) 1995 - First Pre-approval Inspection by FDA

More information

Strategies for Risk Based Validation of Laboratory Systems

Strategies for Risk Based Validation of Laboratory Systems Strategies for Risk Based Validation of Laboratory Systems Video Web Seminar September 23, 2004 Ludwig Huber E-mail: ludwig_huber@agilent.com Today s Agenda Background information: why risk assessment,

More information

HIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005

HIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or

More information

LEADING VERTICALLY INTEGRATED GENERIC PLAYER

LEADING VERTICALLY INTEGRATED GENERIC PLAYER LEADING VERTICALLY INTEGRATED GENERIC PLAYER March 2018 Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation

More information

MDSAP Me M dical D e D vice S i S ngle Audit Program

MDSAP Me M dical D e D vice S i S ngle Audit Program MDSAP Medical Device Single Audit Program Gary Minks VP, Quality & Regulatory Affairs TÜV SÜD America Inc. gminks@tuvam.com Revision: 2013(09(29 TÜV SÜD America 13(04(29 Slide 1 IMDRF International Medical

More information

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION Reprinted from FDA s website by ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION ANDA: APPLICANT: RELATED APPLICATION(S): DRUG NAME: DOSAGE FORM: LETTER DATE:

More information

A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions

A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions 2011 SAS Health & Life Sciences Conference Michelle Combs, PhD, VP, Clinical Pharmacology Sciences, Celerion Bernd Doetzkies,

More information

High Quality or Poor Quality DB

High Quality or Poor Quality DB The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,

More information

Explore the World of End-to-End. Integrated Lab Performance

Explore the World of End-to-End. Integrated Lab Performance Explore the World of End-to-End Integrated Lab Performance Come explore the largest, wholly owned network of BioPharma dedicated laboratories in the world. Discovery/Pharmacology Pre-Clinical/Early Development

More information

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE

More information

Clinical trials: Prerequisites

Clinical trials: Prerequisites Clinical trials: Prerequisites Albiruni R Abdul Razak Staff Medical Oncologist, Princess Margaret Cancer Centre/ Mount Sinai Hospital Assistant Professor, University of Toronto Disclosures Research Funding

More information

By: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos,

By: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos, By: Augustine Onyeaghala Clinical Research/Quality Management Systems Consultant Global Health Trial Workshop Lagos, Email: aonyeaghala@ymail.com. Understand different regulations governing laboratory

More information

Impact of MRCT after ICH E17 fully implement -Industry perspective-

Impact of MRCT after ICH E17 fully implement -Industry perspective- Impact of MRCT after ICH E17 fully implement -Industry perspective- 5th Joint Conference of Taiwan and Japan on Medical Products Regulation December 1st, 2017 Chikara Kikuchi Vice-Chairperson, Drug Evaluation

More information

Pharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai

Pharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai Dayanidhi B, Amol S School of Pharmacy and Technology Management, NMiMS University, Mumbai The US$65-billion (in 2005), global R&D pie is expected to grow to US$l00-billion by 2010. If India secures even

More information

Cadila Healthcare Limited Investor Presentation November 2012

Cadila Healthcare Limited Investor Presentation November 2012 Cadila Healthcare Limited Investor Presentation November 2012 Well integrated pharma player with global footprints ~60 years Operational experience $ 1 bn + Global Revenues >6% of sales Spent on R&D annually

More information

ANALYTICAL STANDARDS AND REAGENTS

ANALYTICAL STANDARDS AND REAGENTS ANALYTICAL STANDARDS AND REAGENTS productivity future growth globalization compliance Waters, the industry leader in liquid chromatography and mass spectrometry, understands that standards and reagents

More information

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION

ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION Reprinted from FDA s website by EAS Consulting Group, LLC ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION ANDA: APPLICANT: RELATED APPLICATION(S): DRUG NAME:

More information

Clinical Data Management Services

Clinical Data Management Services Clinsoft Overview Clinical Trial Management Clinical Data Management Services Medical Writing & Pharmacovigilance Services 2 Overview Started in 2008 with a small group of 7 team members. Expanded to a

More information

AdaptDose, an innovative platform that reduces product development time and costs by 30% or more

AdaptDose, an innovative platform that reduces product development time and costs by 30% or more WHITE PAPER January 2017 AdaptDose, an innovative platform that reduces product development time and costs by 30% or more Frontida BioPharm, Inc. Ron Connolly 01.01.2017 CONTENTS ABSTRACT INTRODUCTION

More information

Indian Pharmaceutical Industry. January 2018

Indian Pharmaceutical Industry. January 2018 Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400

More information

HUMAN CHALLENGE TESTING

HUMAN CHALLENGE TESTING HUMAN CHALLENGE TESTING CLINICAL RESEARCH SOLUTIONS DE-RISKING Faced with increasing pressures on timelines and budgets, clinical research practices need to continuously evolve in order to ensure pipeline

More information

Prequalification of Medicines Programme

Prequalification of Medicines Programme Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General

More information

The Lifecycle of a Sample

The Lifecycle of a Sample The Lifecycle of a Sample Samples are the basis by which all research decisions are made. By following best practices in data management, it is possible to optimise collections, minimise the effect of

More information

Common BA/BE Inspection Observations and Scientific Evaluation

Common BA/BE Inspection Observations and Scientific Evaluation Common BA/BE Inspection Observations and Scientific Evaluation Ruben C. Ayala, Pharm.D. Lead Pharmacologist Division of New Drug Bioequivalence Evaluation Office of Study Integrity and Surveillance (OSIS)

More information

KPI ENCYCLOPEDIA. A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS

KPI ENCYCLOPEDIA. A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS KPI ENCYCLOPEDIA A Comprehensive Collection of KPI Definitions for PHARMACEUTICALS www.opsdog.com info@opsdog.com 844.650.2888 Table of Contents Pharmaceuticals KPI Encyclopedia Pharmaceuticals Metric

More information

CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity

CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2015 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details about

More information

The Best Companion! KOREA MEDICINE RESEARCH INSTITUTE - CRO Based on Reliability and Promise, KMRI will accompany you

The Best Companion! KOREA MEDICINE RESEARCH INSTITUTE - CRO Based on Reliability and Promise, KMRI will accompany you www.kmri.co.kr The Best Companion! KOREA MEDICINE RESEARCH INSTITUTE - CRO Based on Reliability and Promise, KMRI will accompany you Introduction The field of life science now is estimated to be important

More information

WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory

WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory SOP 408.4 Annex D 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int WHO PUBLIC INSPECTION REPORT (WHOPIR) Quality Control Laboratory Part

More information

Industrialized Clinical Data Standards Management Speed of automation, Power of accuracy and Transforming clinical data into business intelligence

Industrialized Clinical Data Standards Management Speed of automation, Power of accuracy and Transforming clinical data into business intelligence Industrialized Clinical Standards Management Speed of automation, Power of accuracy and Transforming clinical data into business intelligence Executive Summary The majority of commercially available legacy

More information

Altascientist. The. Hybrid Medicines and 505(b)(2) NDA Approval Pathways. In this issue DECEMBER 2018 ISSUE NO. 6

Altascientist. The. Hybrid Medicines and 505(b)(2) NDA Approval Pathways. In this issue DECEMBER 2018 ISSUE NO. 6 The Altascientist DECEMBER 2018 ISSUE NO. 6 Hybrid Medicines and 505(b)(2) NDA Approval Pathways Hybrid medicines in the EU, and drugs approved via the 505(b)(2) pathway in the USA, are alike in their

More information

Session 7 Clinical Trial Assessment Bioequivalence Studies

Session 7 Clinical Trial Assessment Bioequivalence Studies L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

BIOANALYTICAL STRATEGY FOR IN VITRO METABOLITE SCREENING WITH EXACT MASS USING THE Q-Tof micro. Jose M. Castro-Perez 1, Carina Leandersson 2

BIOANALYTICAL STRATEGY FOR IN VITRO METABOLITE SCREENING WITH EXACT MASS USING THE Q-Tof micro. Jose M. Castro-Perez 1, Carina Leandersson 2 In metabolism studies, it is vital to understand how a particular drug is absorbed, distributed, metabolised, and eliminated by the body. Metabolite identification is a very important part of the drug

More information

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies

Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Nageshwar R Thudi Ph.D. Director-Clinical R&D Teva Pharmaceuticals Disclaimer The views expressed herein are the views

More information

Company, Position & Person Profile. Cadila Healthcare Limited 6/10/15

Company, Position & Person Profile. Cadila Healthcare Limited 6/10/15 Company, Position & Person Profile Cadila Healthcare Limited 6/10/15 About Zydus Cadila Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value

More information

At LATITUDE, we only do one thing, and we do it very well.

At LATITUDE, we only do one thing, and we do it very well. Formulation Experts for Insoluble Compounds At LATITUDE, we only do one thing, and we do it very well. LATITUDE Pharmaceuticals Inc. has been tackling the most difficult drug formulation challenges for

More information

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia "From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS

More information

Formulation Development Services. Your trust is our reward

Formulation Development Services. Your trust is our reward Formulation Development Services. Your trust is our reward Index Who we are? Mission and Vision Where we can help you? Infrastructure and Systems Site Plan Services we offer Technologies we practice Quality

More information

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements

More information

Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers of diagnostic products, vaccines, finished pharmaceutical products and active

Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers of diagnostic products, vaccines, finished pharmaceutical products and active Joint UNICEF, UNFPA & WHO meeting with manufacturers and suppliers of diagnostic products, vaccines, finished pharmaceutical products and active pharmaceutical ingredients Copenhagen, Denmark 23 26 November

More information

Review Article. Regulatory Consideration for BA/BE Studies in Indian Scenario.

Review Article. Regulatory Consideration for BA/BE Studies in Indian Scenario. Available online at www.jcpronline.in Journal of Current Pharma Research 4 (4), 2014, 1302-1308. Review Article Regulatory Consideration for BA/BE Studies in Indian Scenario. S.T. Mane, A.D. Kshirsagar*,

More information

Your Complete Quality Solution Provider for the Life Science Industry

Your Complete Quality Solution Provider for the Life Science Industry Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,

More information

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,

More information

CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES

CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP STEVE PICCOLI, BMS RAND JENKINS,

More information

India as an Outsourcing Frontier in Biotechnology

India as an Outsourcing Frontier in Biotechnology 1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation

More information